LIVING-DONOR LIVER TRANSPLANTATION WITH INFERIOR VENA CAVA REPLACEMENT IN A PEDIATRIC RECIPIENT WITH ADVANCED HEPATOBLASTOMA


Creative Commons License

Memmedli A., Ateş U., Fitoz Ö. S., Varan A., Kırımker E. O., Karayalçın M. K., ...Daha Fazla

25 th EUPSA CONGRESS, Bologna, İtalya, 12 - 15 Haziran 2024, ss.279-280

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Bologna
  • Basıldığı Ülke: İtalya
  • Sayfa Sayıları: ss.279-280
  • Ankara Üniversitesi Adresli: Evet

Özet

Aim of the study Complete resection is crucial for the cure of hepatoblastoma. Total hepatectomy and liver transplantation is the only option for unresectable hepatoblastoma . In LDLT for advanced hepatoblastoma with retrohepatic IVC invasion, reconstruction of the recipient IVC is necessary. Herein, we present a case of pediatric LDLT with IVC homograft replacement for advanced hepatoblastoma. Case description: The patient was a 20-kg, 4-year-old boy suffering from multifocal hepatoblastoma with invasion of retrohepatic IVC, unresponsive to neoadjuvant chemotherapy. The α-feto-protein level of the patient was 365.000. The patient underwent LDLT with left liver lobe(LL) procured from his uncle. TH with retrohepatic IVC excision was performed. A 7 cm-long and two cm-wide, cold stored, fresh(5 days old ) IVC homograft was anastomosed to supra-hepatic IVC and infra-hepatic IVC after total clamping of suprahepatic and infrahepatic IVC. While waiting to procure the LL graft from the donor, a transient portocaval shunt was done. 382g LL graft was implanted, HV anastomosis was done by creating a wide three-dimensional opening on the IVC graft.Portal vein and hepatic artery anastomoses were done in standard fashion. A duct-to-duct anastomosis was done to reconstruct the bile duct.The patient was discharged three weeks after LDLT, and his α-feto-protein level decreased to normal in six weeks. The patient is doing well during six months of follow-up. Conclusion: TH with retrohepatic IVC resection and replacement is a feasible option for pediatric LDLT for advanced hepatoblastoma. LDLT eliminates the risks of tumor relapse during prolonged waiting times for cadaveric liver grafts.